[go: up one dir, main page]

AR127371A2 - Receptores quiméricos de flt3 y métodos para usarlos - Google Patents

Receptores quiméricos de flt3 y métodos para usarlos

Info

Publication number
AR127371A2
AR127371A2 ARP220102800A ARP220102800A AR127371A2 AR 127371 A2 AR127371 A2 AR 127371A2 AR P220102800 A ARP220102800 A AR P220102800A AR P220102800 A ARP220102800 A AR P220102800A AR 127371 A2 AR127371 A2 AR 127371A2
Authority
AR
Argentina
Prior art keywords
clone
sequence
amino acid
seq
heavy chain
Prior art date
Application number
ARP220102800A
Other languages
English (en)
Inventor
Alice Bakker
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR127371A2 publication Critical patent/AR127371A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)

Abstract

Se divulgan moléculas de unión a antígenos, receptores quiméricos y células inmunes modificadas para FLT3 de acuerdo con la invención. La invención se relaciona además con vectores, composiciones y métodos de tratamiento y/o detección usando las moléculas de unión a antígenos de FLT3 y células inmunes modificadas. Reivindicación 1: Un receptor de un antígeno quimérico que comprende una molécula de unión al antígeno que se une específicamente a FLT3, caracterizado porque la molécula de unión al antígeno comprende: a) una CDR1 de la cadena pesada variable que comprende una secuencia de aminoácidos que no difiere en más de 3, 2, 1 ó 0 residuos de aminoácidos de la secuencia de la SEQ ID Nº 17; o b) una CDR2 de la cadena pesada variable que comprende una secuencia de aminoácidos que no difiere en más de 3, 2, 1 ó 0 residuos de aminoácidos de la secuencia de la SEQ ID Nº 18 o la SEQ ID Nº 26; o c) una CDR3 de la cadena pesada variable que comprende una secuencia de aminoácidos que no difiere en más de 3, 2, 1 ó 0 residuos de aminoácidos de la secuencia de la SEQ ID Nº 19 o la SEQ ID Nº 27; o d) una CDR1 de la cadena liviana variable que comprende una secuencia de aminoácidos que no difiere en más de 3, 2, 1 ó 0 residuos de aminoácidos de la secuencia de la SEQ ID Nº 22 o la SEQ ID Nº 30; o e) una CDR2 de la cadena liviana variable que comprende una secuencia de aminoácidos que no difiere en más de 3, 2, 1 ó 0 residuos de aminoácidos de la secuencia de la SEQ ID Nº 23 ó 31; o f) una CDR3 de la cadena liviana variable que comprende una secuencia de aminoácidos que no difiere en más de 3, 2, 1 ó 0 residuos de aminoácidos de la secuencia de la SEQ ID:24 o la SEQ ID Nº 32; o g) una CDR1 de la cadena pesada variable que comprende una secuencia de aminoácidos de una secuencia de la CDR1 de la cadena pesada variable del clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11; o h) una CDR2 de la cadena pesada variable que comprende una secuencia de aminoácidos de una secuencia de la CDR2 de la cadena pesada variable del clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11; o i) una CDR3 de la cadena pesada variable que comprende una secuencia de aminoácidos de una secuencia de la CDR3 de la cadena pesada variable del clon 10E3, del 2E7, del 8B5, del 4E9 o del 11F11; o j) una CDR1 de la cadena liviana variable que comprende una secuencia de aminoácidos de una secuencia de la CDR1 de la cadena liviana variable clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11; o k) una CDR2 de la cadena liviana variable que comprende una secuencia de aminoácidos de una secuencia de la CDR2 de la cadena liviana variable del clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11; o l) una CDR3 de la cadena liviana variable que comprende una secuencia de aminoácidos de una secuencia de la CDR3 de la cadena liviana variable del clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11; o m) una secuencia de la cadena pesada variable que no difiere en más de 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 ó 0 residuos de la secuencia de la cadena pesada variable del clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11; o n) una secuencia de la cadena liviana variable que no difiere en más de 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 ó 0 residuos de la secuencia de la cadena liviana variable del clon 10E3, del clon 2E7, del clon 8B5, del clon 4E9 o del clon 11F11. Reivindicación 12: Un polinucleótido, caracterizado porque codifica el receptor del antígeno quimérico de la reivindicación 1. Reivindicación 13: Un vector, caracterizado porque comprende al polinucleótido de la reivindicación 12. Reivindicación 15: Una célula inmune, caracterizada porque comprende el vector de la reivindicación 13. Reivindicación 21: Una composición farmacéutica, caracterizada porque comprende una célula inmune de la reivindicación 15.
ARP220102800A 2016-04-01 2022-10-14 Receptores quiméricos de flt3 y métodos para usarlos AR127371A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662317219P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
AR127371A2 true AR127371A2 (es) 2024-01-17

Family

ID=58530714

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP170100839A AR109626A1 (es) 2016-04-01 2017-04-03 Receptores quiméricos de flt3 y métodos para usarlos
ARP220102800A AR127371A2 (es) 2016-04-01 2022-10-14 Receptores quiméricos de flt3 y métodos para usarlos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP170100839A AR109626A1 (es) 2016-04-01 2017-04-03 Receptores quiméricos de flt3 y métodos para usarlos

Country Status (26)

Country Link
US (2) US20190183931A1 (es)
EP (1) EP3436479A1 (es)
JP (3) JP2019516352A (es)
KR (2) KR102389096B1 (es)
CN (1) CN109641956A (es)
AR (2) AR109626A1 (es)
AU (3) AU2017240801A1 (es)
BR (1) BR112018070187A8 (es)
CA (1) CA3019655A1 (es)
CL (1) CL2018002792A1 (es)
CO (1) CO2018011804A2 (es)
CR (2) CR20180518A (es)
EA (1) EA201892193A1 (es)
IL (2) IL296966A (es)
MA (1) MA44507A (es)
MX (1) MX2023013729A (es)
MY (2) MY201207A (es)
NZ (1) NZ746925A (es)
PE (2) PE20241061A1 (es)
PH (1) PH12018502118B1 (es)
SA (1) SA518400154B1 (es)
SG (2) SG11201808622SA (es)
TN (1) TN2018000337A1 (es)
TW (2) TW202313669A (es)
UA (1) UA128326C2 (es)
WO (1) WO2017173410A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
HUE054936T2 (hu) 2016-03-31 2021-10-28 Janssen Pharmaceuticals Inc Helyettesített indol-származékok mint a dengue-vírus replikációjának inhibitorai
EA201892216A1 (ru) 2016-03-31 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
PL3436079T3 (pl) * 2016-04-01 2021-12-20 Kite Pharma, Inc. Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
SG11201808403SA (en) 2016-04-01 2018-10-30 Kite Pharma Inc Bcma binding molecules and methods of use thereof
PT3436030T (pt) 2016-04-01 2022-11-18 Amgen Inc Recetores quiméricos e métodos para a sua utilização
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US10730884B2 (en) 2016-04-01 2020-08-04 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11236171B2 (en) 2016-12-21 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US11407715B2 (en) 2017-05-22 2022-08-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
UA125970C2 (uk) 2017-05-22 2022-07-20 Янссен Фармасьютікалз, Інк. Заміщені похідні індоліну як інгібітори реплікації вірусів денге
CN110831970B (zh) * 2017-06-02 2024-12-17 辉瑞公司 靶向flt3的嵌合抗原受体
PL3661954T3 (pl) 2017-08-03 2022-05-16 Amgen Inc. Muteiny interleukiny 21 i sposoby leczenia
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
CN111727197A (zh) 2018-01-12 2020-09-29 美国安进公司 抗pd-1抗体和治疗方法
WO2019180724A1 (en) * 2018-03-23 2019-09-26 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing membrane-bound il-10
JOP20200259A1 (ar) * 2018-04-10 2020-10-11 Kite Pharma Inc مستقبلات خيمرية لـ dll3 وطرق استخدامها
CN112292400A (zh) * 2018-04-13 2021-01-29 桑格摩生物治疗法国公司 对白介素-23受体特异的嵌合抗原受体
PE20211474A1 (es) 2018-12-18 2021-08-05 Boehringer Ingelheim Io Canada Inc Anticuerpos agonistas de flt3 y usos de estos
US20220160771A1 (en) * 2019-04-10 2022-05-26 Iulia Diaconu Flt3-specific chimeric antigen receptors and methods of using the same
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
CA3161103A1 (en) * 2019-12-16 2021-06-24 Carl Deselm Chimeric antigen receptor dendritic cells (car-dcs) and methods of making and using same
WO2021212069A1 (en) * 2020-04-17 2021-10-21 City Of Hope Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies
CN111808821B (zh) * 2020-06-24 2022-06-14 南方医科大学珠江医院 Flt3-nkg2d双靶点car-t的构建与制备
CA3201115A1 (en) 2020-12-21 2022-06-30 Shanshan LANG Protease-activating cd45-gate car
MX2023008662A (es) * 2021-01-28 2023-08-01 Allogene Therapeutics Inc Metodos para transducir celulas inmunitarias.
MX2023008809A (es) 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
CN116410315A (zh) * 2021-12-31 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用
CN119654406A (zh) 2022-07-29 2025-03-18 艾洛基治疗公司 具有降低的基因表达以减轻免疫细胞识别的经工程化的细胞
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
CN120157768A (zh) * 2023-12-15 2025-06-17 博生吉安科细胞技术有限公司 一种识别flt3-car分子的单克隆抗体及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1047770A1 (zh) 2000-02-24 2003-03-07 Xcyte Therapies, Inc. 细胞的同时刺激与浓缩
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
NO345919B1 (no) * 2005-08-26 2021-10-18 Roche Glycart Ag Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
BR112012015740B1 (pt) * 2009-12-23 2020-09-29 Synimmune Gmbh Anticorpo anti-flt3, seu uso,bem como composição compreendendo o referido anticorpo e molécula de ácido nucleico
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
US9845362B2 (en) * 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012103279A2 (en) 2011-01-26 2012-08-02 Ariad Pharmaceuticals, Incorporated Methods and compositions for the synthesis of multimerizing agents
NZ743310A (en) 2011-03-23 2022-11-25 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
CA2868121C (en) * 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
KR102064230B1 (ko) 2013-02-15 2020-01-13 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
KR20150131218A (ko) 2013-03-14 2015-11-24 벨리쿰 파마슈티컬스, 인크. T 세포 증식의 제어 방법
CA2956667A1 (en) 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
JP6793902B2 (ja) 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
CN106132423B (zh) 2014-02-14 2020-07-31 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
ES2939760T3 (es) * 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
MX377344B (es) * 2014-07-31 2025-03-07 Amgen Res Munich Gmbh Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas.
IL292650B2 (en) * 2014-09-19 2024-04-01 Hope City COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
TWI829617B (zh) * 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
PL3436079T3 (pl) * 2016-04-01 2021-12-20 Kite Pharma, Inc. Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania

Also Published As

Publication number Publication date
JP2024105337A (ja) 2024-08-06
IL262061B2 (en) 2023-03-01
CR20180518A (es) 2019-04-25
AU2017240801A8 (en) 2018-11-29
NZ746925A (en) 2023-06-30
CN109641956A (zh) 2019-04-16
SG11201808622SA (en) 2018-10-30
PH12018502118B1 (en) 2024-02-23
IL296966A (en) 2022-12-01
TW201803897A (zh) 2018-02-01
US20230124464A1 (en) 2023-04-20
IL262061B (en) 2022-11-01
AU2024278538A1 (en) 2025-01-30
CR20240116A (es) 2024-04-12
TN2018000337A1 (en) 2020-01-16
PE20190201A1 (es) 2019-02-05
AU2022200108A1 (en) 2022-02-03
CO2018011804A2 (es) 2019-02-08
AR109626A1 (es) 2019-01-09
PE20241061A1 (es) 2024-05-13
KR20190021203A (ko) 2019-03-05
BR112018070187A8 (pt) 2019-11-05
EA201892193A1 (ru) 2019-06-28
SG10201911963VA (en) 2020-02-27
JP2019516352A (ja) 2019-06-20
SA518400154B1 (ar) 2022-11-09
CL2018002792A1 (es) 2019-04-26
PH12018502118A1 (en) 2019-07-08
BR112018070187A2 (pt) 2019-01-29
WO2017173410A1 (en) 2017-10-05
CA3019655A1 (en) 2017-10-05
KR102694879B1 (ko) 2024-08-16
AU2022200108C1 (en) 2025-07-31
MA44507A (fr) 2019-02-06
MY201207A (en) 2024-02-09
TW202313669A (zh) 2023-04-01
AU2017240801A1 (en) 2018-10-25
KR20220054453A (ko) 2022-05-02
JP2022091793A (ja) 2022-06-21
AU2022200108B2 (en) 2024-09-19
EP3436479A1 (en) 2019-02-06
IL262061A (en) 2018-11-29
UA128326C2 (uk) 2024-06-12
JP7561155B2 (ja) 2024-10-03
MY210545A (en) 2025-09-30
TWI776807B (zh) 2022-09-11
KR102389096B1 (ko) 2022-04-25
WO2017173410A9 (en) 2017-12-14
MX2023013729A (es) 2023-11-28
US20190183931A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
AR127371A2 (es) Receptores quiméricos de flt3 y métodos para usarlos
AR108066A1 (es) Receptores quiméricos para cll-1 y métodos de uso de los mismos
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20220495A1 (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
AR101829A1 (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
MX2023007045A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
EA202091710A1 (ru) Антитела против cd73 и способы их применения
PE20181451A1 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
PE20180481A1 (es) Anticuerpos de union a tau
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
MD4716B1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
AR106949A1 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20250416A1 (es) Composiciones y metodos de inhibicion del masp-3 para el tratamiento de diversas enfermedades y trastornos
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
AR103891A1 (es) Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden
PE20190737A1 (es) Anticuerpos anti-cd27
PE20200610A1 (es) Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales
AR075504A1 (es) Moleculas de anticuerpos que tienen especificidad para el ox40 humano
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos